AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7923645 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with Hirudin
Number of subjects: 2564
Study 7923645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both thrombin inhibitors
Number of subjects: 2564
Study 2468874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg b.i.d.
Number of subjects: 605
Study 2468874 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg q.d.
Number of subjects: 605
Study 2468874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 5‐20 mg b.i.d.
Number of subjects: 605
Study 2468874 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40‐120 mg b.i.d.
Number of subjects: 605
Study 30883517 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept-treated patients with aTCMR
Number of subjects: 20
Study 30883517 — intervention group
Group type: COMPARATOR
Intervention: Belatacept-treated patients without aTCMR
Number of subjects: 20
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: IL13
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-RAGE
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: CFH
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: IL18
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: IL17
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: complement 3
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFRII
Number of subjects: 971
Study 28258520 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1ra
Number of subjects: 971
Study 25091221 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cycle induced with oestradiol and progesterone supplementation (n = 291)
Number of subjects: 576
Study 25091221 — intervention group
Group type: COMPARATOR
Intervention: Stimulated cycle induced by human menopausal gonadotrophin (HMG) (n = 285)
Number of subjects: 576
Study 23650884 — intervention group
Group type: EXPERIMENTAL
Intervention: Grammar treatment (experimental group)
Number of subjects: 34
Study 23650884 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (control group)
Number of subjects: 34
Study 21216560 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentectomy with preservation of the right gastro‐epiploic artery (GEA)
Number of subjects: 42
Study 21216560 — intervention group
Group type: COMPARATOR
Intervention: Omentectomy with resection of the right gastro‐epiploic artery (GEA)
Number of subjects: 42
Study 19082322 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV with bilevel pressure for 30 minutes after extubation
Number of subjects: 100
Study 19082322 — intervention group
Group type: COMPARATOR
Intervention: Nasal O2 catheter
Number of subjects: 100
Study 16931989 — intervention group
Group type: EXPERIMENTAL
Intervention: Active left prefrontal repetitive transcranial magnetic stimulation
Number of subjects: 20
Study 16931989 — intervention group
Group type: COMPARATOR
Intervention: Sham left prefrontal repetitive transcranial magnetic stimulation
Number of subjects: 20
Study 15138095 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate group (lactate > 2 mmol/L)
Number of subjects: 776
Study 11052960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia of 70 mg/dl
Number of subjects: 15
Study 11052960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia of 60 mg/dl
Number of subjects: 15
Study 11052960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia of 50 mg/dl
Number of subjects: 15
Study 11052960 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic control studies
Number of subjects: 15
Study 11052960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia of 70, 60, and 50 mg/dl
Number of subjects: 15
Study 11052960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia of 60 and 50 mg/dl
Number of subjects: 15
Study 9357875 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 67
Study 9357875 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 67
Study 9357875 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 67
Study 9357875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 67
Study 9357875 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 67
Study 9357875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 8259037 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 3 MU three times weekly for 3 months, increased to 6 MU for non-responders for an additional 3 months
Number of subjects: 30
Study 8259037 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 3 MU three times weekly
Number of subjects: 30
Study 8259037 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dosage of interferon to 6 MU for non-responders
Number of subjects: 30
Study 8259037 — intervention group
Group type: COMPARATOR
Intervention: Baseline 2‐5 OAS serum activity
Number of subjects: 30
Study 8259037 — intervention group
Group type: COMPARATOR
Intervention: Follow-up on untreated cases
Number of subjects: 30
Study 3936739 — intervention group
Group type: EXPERIMENTAL
Intervention: buccal nitroglycerin
Number of subjects: 14
Study 3936739 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 31056640 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop technique
Number of subjects: 80
Study 31056640 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (no loop technique)
Number of subjects: 80
Study 28610897 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 127
Study 28610897 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 127
Study 25986427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat preload (30 ml olive oil)
Number of subjects: 10
Study 25986427 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein preload (55 g whey protein)
Number of subjects: 10
Study 25986427 — intervention group
Group type: COMPARATOR
Intervention: Water preload
Number of subjects: 10
Study 25173342 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multivitamin supplementation
Number of subjects: 874
Study 25173342 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A supplementation
Number of subjects: 874
Study 22576112 — intervention group
Group type: EXPERIMENTAL
Intervention: Real MRI
Number of subjects: 24
Study 22576112 — intervention group
Group type: COMPARATOR
Intervention: Sham MRI
Number of subjects: 24
Study 20091111 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program; Importance of nutrition highlighted
Number of subjects: 186
Study 20091111 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy for academic problems; Importance of problems rated by participants
Number of subjects: 186
Study 17822830 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS courses with conventional manikins plus live actors (group A)
Number of subjects: 225
Study 17822830 — intervention group
Group type: COMPARATOR
Intervention: ACLS courses with conventional manikins (group B)
Number of subjects: 225
Study 15963202 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas compartment block (group P)
Number of subjects: 50
Study 15963202 — intervention group
Group type: COMPARATOR
Intervention: Femoral block (group F)
Number of subjects: 50
Study 12500103 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 12500103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11207870 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (9 g)
Number of subjects: 10
Study 11207870 — intervention group
Group type: COMPARATOR
Intervention: Control (without guar gum)
Number of subjects: 10
Study 9554530 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-view mammography without physical examination (67,656 women)
Number of subjects: 166600
Study 9554530 — intervention group
Group type: COMPARATOR
Intervention: Observation (97,294 women, control group)
Number of subjects: 166600
Study 9554530 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened women
Number of subjects: 166600
Study 7525628 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IU GH/m2.day
Number of subjects: 23
Study 7525628 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU GH/m2.day
Number of subjects: 23
Study 3619386 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) with heparin (5,000 U IV bolus, followed by 150,000 IU UK IV bolus, then 12,000 IU UK/min for 90 min, total dose 1,230,000 IU)
Number of subjects: 31
Study 3619386 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (5,000 U IV bolus)
Number of subjects: 31
Study 3619386 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK)
Number of subjects: 31
Study 3619386 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 31
Study 28898388 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention from the Bucharest Early Intervention Project
Number of subjects: 150
Study 28121706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg daily
Number of subjects: 213
Study 28121706 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg daily
Number of subjects: 213
Study 26780276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg) daily for three months
Number of subjects: 124
Study 26780276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22750632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 25 µg
Number of subjects: 20
Study 22750632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 50 µg
Number of subjects: 20
Study 22750632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg
Number of subjects: 20
Study 22750632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg
Number of subjects: 20
Study 22750632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22750632 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 21825298 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg peramivir
Number of subjects: 1091
Study 21825298 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg peramivir
Number of subjects: 1091
Study 21825298 — intervention group
Group type: COMPARATOR
Intervention: oseltamivir (75 mg b.i.d. for 5 days)
Number of subjects: 1091
Study 18647506 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional application of acidulated phosphate fluoride (APF) gel followed by drinking a glass of water
Number of subjects: 0
Study 18647506 — intervention group
Group type: COMPARATOR
Intervention: Professional application of acidulated phosphate fluoride (APF) gel without rinsing, drinking, or eating
Number of subjects: 0
Study 16832270 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic embolization (AE) added to nonoperative management (NOM)
Number of subjects: 133
Study 16832270 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic embolization (AE)
Number of subjects: 133
Study 16832270 — intervention group
Group type: COMPARATOR
Intervention: Control group (before AE)
Number of subjects: 133
Study 16832270 — intervention group
Group type: COMPARATOR
Intervention: Control group (after AE)
Number of subjects: 133
Study 15017503 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg clonidine twice a day
Number of subjects: 44
Study 15017503 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg clonidine twice a day
Number of subjects: 44
Study 15017503 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg clonidine twice a day
Number of subjects: 44
Study 15017503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10706232 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin‐mineral supplementation at 50% of the U.S. daily recommended allowance (RDA) for 3 months
Number of subjects: 245
Study 10706232 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 245
Study 9343030 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm nitric oxide
Number of subjects: 33
Study 9343030 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ppm nitric oxide
Number of subjects: 33
Study 9343030 — intervention group
Group type: COMPARATOR
Intervention: Control (no nitric oxide)
Number of subjects: 33
Study 9343030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm) in patients with left ventricular ejection fractions > 0.25
Number of subjects: 33
Study 9343030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm) in patients with left ventricular ejection fractions <= 0.25
Number of subjects: 33
Study 8230075 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sugar solution preparation by mothers
Number of subjects: 274
Study 29892986 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 52
Study 29892986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28057652 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior foraminotomy (FOR)
Number of subjects: 308
Study 28057652 — intervention group
Group type: COMPARATOR
Intervention: Anterior discectomy with fusion (ACDF)
Number of subjects: 308
Study 25174865 — intervention group
Group type: EXPERIMENTAL
Intervention: Feno-driven controlled asthma (FCa) strategy (ACQ score <0.75 and Feno value <25 ppb)
Number of subjects: 611
Study 25174865 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly controlled asthma (PCa) strategy (ACQ score <1.50)
Number of subjects: 611
Study 25174865 — intervention group
Group type: COMPARATOR
Intervention: Controlled asthma (Ca) strategy (ACQ score <0.75)
Number of subjects: 611
Study 23216045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) plus treatment as usual (TAU)
Number of subjects: 95
Study 23216045 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 95
Study 22015877 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor room
Number of subjects: 15
Study 22015877 — intervention group
Group type: COMPARATOR
Intervention: Operating room
Number of subjects: 15
Study 18360014 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 797
Study 18360014 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 797
Study 17140543 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol tablets (1-2 tablets per day, 0.5-1g) for 1.5 years
Number of subjects: 132
Study 17140543 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 132
Study 17140543 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol tablets
Number of subjects: 132
Study 12579592 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 6-minute gait distance
Number of subjects: 65
Study 12579592 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 65
Study 12579592 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion
Number of subjects: 65
Study 11852651 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburban community medical center
Number of subjects: 206
Study 11852651 — intervention group
Group type: COMPARATOR
Intervention: Urban hospital
Number of subjects: 206
Study 11852651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairman's Talk
Number of subjects: 206
Study 11852651 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Session
Number of subjects: 206
Study 11852651 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking with current residents
Number of subjects: 206
Study 8737885 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% emulsion of oil of bitter orange (OBO) three times daily
Number of subjects: 60
Study 8737885 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% OBO in alcohol three times daily
Number of subjects: 60
Study 8737885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure OBO, once daily
Number of subjects: 60
Study 1389848 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg i.v. before surgery, followed by 100 mg rectally 6 and 12 h after surgery and at 08:00, 16:00 and 23:00 on the next day
Number of subjects: 56
Study 1389848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2581599 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment (25 mg four times daily for 4 days)
Number of subjects: 8
Study 2581599 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment (one matched capsule four times daily for 4 days)
Number of subjects: 8
Study 2581599 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment
Number of subjects: 8
Study 2581599 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 8
Study 30419934 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised, multifaceted quality improvement (QI) intervention for cardiovascular disease management
Number of subjects: 30
Study 30419934 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 26912438 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MAA (macroaggregated serum albumin)
Number of subjects: 24
Study 26912438 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HSA (human serum albumin)
Number of subjects: 24
Study 24052326 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Psoriasis Symptom Inventory
Number of subjects: 80
Study 24052326 — intervention group
Group type: COMPARATOR
Intervention: Paper Psoriasis Symptom Inventory
Number of subjects: 80
Study 22863612 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Jointz (3.5 g/day, thrice daily)
Number of subjects: 133
Study 22863612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 20139789 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping once daily (J1x)
Number of subjects: 21
Study 20139789 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping twice daily (J2x)
Number of subjects: 21
Study 20139789 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal strength training)
Number of subjects: 21
Study 17075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin‐alpha1 (T‐alpha1) 1.6 mg subcutaneously, twice a week for six months
Number of subjects: 62
Study 17075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN‐alpha) 5 MU daily for 15 days, then three times weekly for six months
Number of subjects: 62
Study 17075991 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (untreated with IFN‐alpha)
Number of subjects: 62
Study 17075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin‐alpha1 (T‐alpha1)
Number of subjects: 62
Study 17075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN‐alpha)
Number of subjects: 62
Study 15589860 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (7.5 mg daily)
Number of subjects: 238
Study 15589860 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (100 mg daily)
Number of subjects: 238
Study 15589860 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness in Letrozole group
Number of subjects: 238
Study 15589860 — intervention group
Group type: COMPARATOR
Intervention: Endometrial thickness in Clomiphene Citrate group
Number of subjects: 238
Study 11342470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng/mL lipopolysaccharide (LPS) stimulation in group 1A
Number of subjects: 32
Study 11342470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng/mL lipopolysaccharide (LPS) stimulation in group 1B
Number of subjects: 32
Study 11342470 — intervention group
Group type: COMPARATOR
Intervention: 1 ng/mL lipopolysaccharide (LPS) stimulation in group 2 (chronic stable angina)
Number of subjects: 32
Study 11342470 — intervention group
Group type: COMPARATOR
Intervention: 1 ng/mL lipopolysaccharide (LPS) stimulation in group 3 (healthy subjects)
Number of subjects: 32
Study 9412887 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (loading dose 2 mg/kg, maintenance infusion 7.5 micrograms/kg/min)
Number of subjects: 32
Study 9412887 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 32
Study 9412887 — intervention group
Group type: COMPARATOR
Intervention: Dopamine-nitroglycerin (dopamine 5 micrograms/kg/min, nitroglycerin 1 microgram/kg/min)
Number of subjects: 32
Study 8485266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) (> or = 7 mg.kg/day)
Number of subjects: 1949
Study 8485266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ursodeoxycholic acid (UDCA) (< 7 mg.kg/day)
Number of subjects: 1949
Study 8485266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chenodeoxycholic acid (CDCA) (> or = 10 mg.kg/day)
Number of subjects: 1949
Study 8485266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (UDCA + CDCA)
Number of subjects: 1949
Study 8485266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1949
Study 8485266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chenodeoxycholic acid (CDCA) (< 10 mg.kg/day)
Number of subjects: 1949
Study 3436104 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip test at 30% of maximal voluntary contraction for 90 seconds at 30 min intervals
Number of subjects: 14
Study 3436104 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip test at 30% of maximal voluntary contraction for 90 seconds at 24 h intervals
Number of subjects: 14
Study 3436104 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing product strength x duration of handgrip test
Number of subjects: 14
Study 3436104 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant product strength x duration of handgrip test
Number of subjects: 14
Study 31172979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w (Mw) vaccine
Number of subjects: 64
Study 31172979 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified protein derivative (PPD) of tuberculin antigen
Number of subjects: 64